A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer

NCT04380103 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

106

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Cancer
Colorectal Cancer
Colorectal Adenocarcinoma

Interventions

DRUG: XELOXIRI/Bevacizumab

Sponsor

Chinese Academy of Medical Sciences